PARP1 Protein

Introduction

Parp1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

PARP1 (Poly(ADP-ribose) Polymerase 1) is a 113 kDa nuclear enzyme that catalyzes the transfer of ADP-ribose units from NAD+ to target proteins. This post-translational modification, known as poly(ADP-ribos)ylation (PARylation), plays critical roles in DNA repair, genomic stability, cell death pathways, and neuroinflammation. PARP1 is the most abundant and well-characterized member of the PARP enzyme family.

Structure

PARP1 has a modular structure:

• N-terminal DNA-binding domain: Contains two zinc fingers that recognize DNA strand breaks

• Central automodification domain: Sites for auto-PARylation

• C-terminal catalytic domain: Catalyzes NAD+-dependent ADP-ribosylation

Crystal structures reveal the catalytic domain adopts an ADP-ribosyltransferase (ART) fold. The active site contains a conserved H-Y-E triplet motif (His-862, Tyr-896, Glu-988 in human PARP1) essential for catalysis.

Normal Function

In the nervous system, PARP1 functions include:

• DNA Damage Repair: Primary sensor of single and double-strand DNA breaks

• Base Excision Repair: Coordinates XRCC1, DNA ligase III, and polymerase beta

• Chromatin Remodeling: PARylation of histones relaxes chromatin for repair

• Transcriptional Regulation: Modifies transcription factors including NF-κB, p53

• Cell Survival: Low-level activation promotes DNA repair and cell survival

Role in Disease

Parkinson’s Disease

PARP1 overactivation contributes to dopaminergic neuron death through:

• Excessive DNA damage from oxidative stress

• NAD+ depletion leading to energy failure

• Parthanatos (PAR-mediated cell death)

• Inhibition of parkin-mediated mitophagy

Therapeutic approaches: PARP inhibitors (PJ-34, DPQ) show neuroprotection in MPTP/6-OHDA models.

ALS

• TDP-43 proteinopathy intersects with PARP1 pathways

• DNA damage accumulates in motor neurons

• PARP1-mediated cell death is a terminal event

• Combined PARP/SIRT1 targeting shows promise

Alzheimer’s Disease

• Aβ induces DNA damage activating PARP1

• Tau pathology affects PARP1 expression

• PARP1-SIRT1 axis dysregulation

• Therapeutic potential of PARP1 inhibition

Stroke

• Ischemia causes massive DNA damage

• PARP1 overactivation depletes NAD+/ATP

• PARP inhibitors reduce infarct size

• Clinical trials ongoing

Therapeutic Targeting

Key Publications

1. “PARP-1 activation in neuronal death” - J Neurochem (2019) ^{1CitationPMID 30767845Open reference}(https://pubmed.ncbi.nlm.nih.gov/30767845/)

2. “Poly(ADP-ribose) polymerase in neurodegeneration” - Prog Neurobiol (2020) ^{2CitationPMID 32068074Open reference}(https://pubmed.ncbi.nlm.nih.gov/32068074/)

3. “PARP inhibition in stroke therapy” - Stroke (2017) ^{3CitationPMID 28082258Open reference}(https://pubmed.ncbi.nlm.nih.gov/28082258/)

4. “PARP-1 and SIRT1 interaction” - Aging Cell (2021) ^{4CitationPMID 33258325Open reference}(https://pubmed.ncbi.nlm.nih.gov/33258325/)

Cross-Links

• PARP1 Gene

• DNA Damage Response Pathway

• Oxidative Stress Pathway

• Parkinson’s Disease

• ALS

External Links

• UniProt: P09874

• PDB: 4DQY

• NCBI Gene: PARP1

Background

The study of Parp1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Alzheimer’s Disease

• Amyloid Hypothesis

• Tau Pathology

• Parkinson’s Disease

• Alpha-Synuclein